Cargando…

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?

SIMPLE SUMMARY: More than ten years after the first publication of the results of the ToGA phase III trial, active research avenues are exploring the role of novel agents targeting human epidermal growth factor receptor 2 (HER2). Preliminary reports have highlighted promising activity for several th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricci, Angela Dalia, Rizzo, Alessandro, Rojas Llimpe, Fabiola Lorena, Di Fabio, Francesca, De Biase, Dario, Rihawi, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036476/ https://www.ncbi.nlm.nih.gov/pubmed/33916206 http://dx.doi.org/10.3390/cancers13071664

Ejemplares similares

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications
por: Rihawi, Karim, et al.
Publicado: (2021)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Paradigm Shift or Shifting Paradigm for Type 1 Diabetes
por: Nakayama, Maki, et al.
Publicado: (2012)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

Radiotherapy for HER 2 Positive Brain Metastases: Urgent Need for a Paradigm Shift
por: Ippolito, Edy, et al.
Publicado: (2022)

Streptomyces in biotechnology: An anotated selection of world wide web sites relevant to the topics in microbial biotechnology
por: Wackett, Lawrence P.
Publicado: (2020)

Fibromuscular Dysplasia: Another Paradigm Shift in Renovascular Hypertension?
por: Takahashi, Katsutoshi, et al.
Publicado: (2018)

Paradigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?
por: Lee, Hae-Young, et al.
Publicado: (2020)

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
por: Fanotto, Valentina, et al.
Publicado: (2016)

Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis
por: Qvist, Tavs, et al.
Publicado: (2014)

Imaging avascular necrosis of bone: “The shifting paradigm”
por: Khan, Shoukat H.
Publicado: (2016)

Rotavirus vaccination and intussusception: a paradigm shift?
por: Vetter, Volker, et al.
Publicado: (2020)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Patient-centred measurement in ophthalmology – a paradigm shift
por: Pesudovs, Konrad
Publicado: (2006)

Commentary: SLET - A paradigm shift in limbal transplantation
por: Vazirani, Jayesh
Publicado: (2019)

Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?
por: Cefalu, William T.
Publicado: (2009)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

A paradigm shift for the prevention and treatment of individual and global obesity
por: Slyper, Arnold H
Publicado: (2018)

To accompany Banas et al., Time for a Paradigm Shift
por: Sharma, Atul K., et al.
Publicado: (2019)

Health Equity and a Paradigm Shift in Occupational Safety and Health
por: Flynn, Michael A., et al.
Publicado: (2021)

A paradigm shift in liquid cooling by multitextured surface design
por: Zhou, Ying, et al.
Publicado: (2022)

A Paradigm Shift from International to Transnational Medical Education
por: Patel, Dhaval, et al.
Publicado: (2023)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer
por: Okines, Dr Alicia FC, et al.
Publicado: (2021)

The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
por: Patel, Aena, et al.
Publicado: (2020)

Advances in glaucoma surgery: Paradigm shift in management
por: Pathak-Ray, Vanita
Publicado: (2016)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Cancer immunotherapy trials: leading a paradigm shift in drug development
por: Emens, Leisha A., et al.
Publicado: (2016)

Shifting paradigm: From “No Code” and “Do-Not-Resuscitate” to “Goals of Care” policies
por: Arabi, Yaseen M., et al.
Publicado: (2018)

Treatment outcome reporting in anorexia nervosa: time for a paradigm shift?
por: Murray, Stuart B., et al.
Publicado: (2018)

Shifting the paradigm: using disease outbreaks to build resilient health systems
por: Durski, Kara N, et al.
Publicado: (2020)

From STEMI to occlusion MI: paradigm shift and ED quality improvement
por: McLaren, Jesse T. T., et al.
Publicado: (2021)

Expanding applications of MRI-based radiomics in HER2-positive breast cancer
por: Park, Vivian Y.
Publicado: (2020)

Role of birth companion in COVID-19: indispensable for her and an auxiliary hand for us
por: Kathuria, Priyanka, et al.
Publicado: (2020)

Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cgb2tf34pa9e6841euoe4afv5t